The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2

Ther Adv Musculoskelet Dis. 2023;15:1759720X231189005 doi: 10.1177/1759720X231189005

Post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 concludes that ixekizumab (IXE) is effective in improving axial symptoms in patients with active PsA presenting with axial manifestations.

In addition to the heterogenous manifestations associated with PsA, such as peripheral arthritis, axial arthritis and enthesitis, some patients also experience symptoms relating to the spine and sacroiliac joint (known as axial manifestations).

Deodhar, et al. aimed to determine the efficacy of IXE up to 52 weeks in reducing axial symptoms in PsA patients, presenting with axial manifestations, in a post-hoc analysis of data from two phase III clinical trials.